RxDoctor Payments Data

Andrea Black, APRN

Family · Reno, NVNPI 1093079998

Payments from drug & device makers

$810in general payments, 2019–2025

Across 38 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$195
  • Boston Scientific$141
  • Saluda Medical Americas, Inc.$102
  • Nevro Corp.$63
  • Pfizer$50
  • Abbott$43
  • plus $216 from 8 others

What the payments were for

  • Food & beverage$79898%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$810 in reported general payments places this provider in the 65th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$91,221
Medicare patients
224
Services billed
8,742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant20$20,980
OxycontinOxycodone Hcl13$20,892
QuliptaAtogepant15$16,595
BelbucaBuprenorphine Hcl14$16,329
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen565$12,407
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen399$10,846
Emgality PenGalcanezumab-Gnlm14$9,698
Gabapentin390$9,697
Pregabalin197$6,471
Buprenorphine17$5,938
SymproicNaldemedine Tosylate12$5,659
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl33$4,277
Fentanyl36$2,764
Lidocaine39$2,659
Celecoxib67$2,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$195$37,57535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,501 family providers in Nevada.

Other family in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →